Category Archives: Latest News from DMC Medical

Nugen™ Marketing

DMC will undertake a major marketing campaign beginning in August 2017 for the Nugen™ syringe range. The prefilled drug market is seeking alternatives to glass syringes/vials with suitable polymers that are BPA free, chemical & lipid resistant with added toughness and glass-like clarity. The Nugen™ syringe is a suitable and cost-effective alternative. DMC will target the major pharma companies in both Europe and the United States currently prefilling drugs and seeking a superior polymer syringe.

Nugen™

Enquiries increase for the BPA Free Nugen™ syringe with evaluation samples going to the United Kingdom, Turkey, Spain, Russia and the United States. Validations can take a number of months depending on what use the syringe is put to and the drug involved.

BPA (Bisphenol A)

As a result of its classification as “reprotox 1B”, which entered into force in August 2016, BPA formally meets the criteria for identification as a Substance of Very High Concern. In December 2016, ECHA’s Member State Committee (MSC) agreed to identify BPA as SVHC, based on its harmonised classification.

The California Office of Environmental Health Hazard Assessment (OEHHA) lists BPA under Proposition 65 Warnings.

DMC Medical collaboration agreement with Eastman Chemical

Following a number of successful discussions DMC Medical have entered into a collaboration agreement with Eastman Chemical that will see DMC trial Eastman’s medical grade copolymer.

The BPA free polymer chosen has superior lipid & chemical resistance in addition to its toughness, clarity and suitability for EtO & Gamma sterilization. Should the trials prove successful, the resulting syringes should be suitable for the medical device & Pharma prefilled markets.